Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores

Claire Ditchfield, Victoria Johnson, Anthony Tighe, +6

The Journal of Cell Biology

GeneticsMolecular BiologyAurora BCell CycleSpindle Checkpoint Function +14

AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with <i>In vitro</i> and <i>In vivo</i> Antitumor Activity

Christine M. Chresta, Barry R. Davies, Ian Hickson, +21

Cancer Research

Mtorc2 Substrate AktCell DeathPharmacotherapyTumor BiologyMtorc1 Substrates +19

Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo

Susan Ashton, Young Ho Song, Elaine Cadogan, +28

Science Translational Medicine

Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS

Sarah J. Ross, Alexey S. Revenko, Lyndsey Hanson, +14

Science Translational Medicine

Imidazo[1,2-a]pyridines: A potent and selective class of cyclin-Dependent kinase inhibitors identified through structure-Based hybridisation

Malcolm Anderson, John F. Beattie, Gloria A. Breault, +11

Bioorganic & Medicinal Chemistry Letters

Cyclin-dependent Kinase InhibitorsMedicinal ChemistryBioorganic ChemistryHeterocyclicBiochemistry +8

Inhibition of PI3Kβ Signaling with AZD8186 Inhibits Growth of PTEN-Deficient Breast and Prostate Tumors Alone and in Combination with Docetaxel

Urs J. Hancox, Sabina Cosulich, Lyndsey Hanson, +21

Molecular Cancer Therapeutics

High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models

Rute B. Marques, Ashraf Aghai, Corrina M.A. de Ridder, +8

European Urology

UrologyOncologyGenitourinary CancerMedicineAndrogen Deprivation +6

Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 1: identification and optimisation of substituted 4,6-Bis anilino pyrimidines

John F. Beattie, Gloria A. Breault, Rebecca Ellston, +8

Bioorganic & Medicinal Chemistry Letters

Medicinal ChemistryCyclin-dependent Kinase 4MedicineNatural SciencesRational Drug Design +7

Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 2: identification and optimisation of substituted 2,4-bis anilino pyrimidines

Gloria A. Breault, Rebecca Ellston, Stephen Green, +7

Bioorganic & Medicinal Chemistry Letters

Medicinal ChemistryCyclin-dependent Kinase 4MedicineNatural SciencesRational Drug Design +7

Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for <i>PIK3CA</i> -Dependent Breast Cancers

Kevin Hudson, Urs J. Hancox, Cath Trigwell, +15

Molecular Cancer Therapeutics